Skip to main content Skip to footer
PipelineReview. Business Intellegence Center
  • Home
  • News Channels
    • Antibodies
    • Proteins and Peptides
    • Vaccines
    • DNA RNA and Cells
    • Small Molecules
    • More News
    • All News
  • Reports
  • Press Room
  • Contact Us
  • About Us

RNA-Targeted Therapeutics

Nov 2022

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

2.350,00€
May 2020

Report Package: “Drug the Undruggable” Technologies

8.250,00€
4.125,00€
Sep 2019

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2.050,00€

Report categories

    Antibody & Protein Sales
    Antibody Technologies
    Biosimilar Antibodies & Proteins
    CAR T-Cells
    Drug the Undruggable Technologies
    Immuno-Oncology
    mRNA Vaccines & Therapeutics
    NK Cells & CAR Macrophages
    Pipeline Database
    RNA-Targeted Therapeutics
    Target Pipelines
    TCR T-Cells and Antibodies
    Therapeutic Antibodies
    Therapeutic Proteins & Peptides
PipelineReview.com is powered by La Merie Business IntelligenceFor immediate assistance, please call us during business hours:
Mon-Fri 10:00am - 05:00pm; GMT+01
La Merie Publishing - Ulrich Martin
Badstrasse 11 | 97990 Weikersheim | Germnay | T +49-176 8016 8139 | Email info@lamerie.com

All contents © by La Merie Publishing

  • Terms and Conditions
    Privacy Policy
    Submit your Press Release
    Imprint
Programa Kit Digital cofinanciado por los fondos Next Generation (EU)
del mecanismo de recuperación y resilencia
NextGeneration-EUPlan de recuperación, transformación y resilencia